AbbVie Q3 growth of >100% in Skyrizi, Rinvoq sales; guides non-GAAP EPS above consensus

• AbbVie (ABBV) Q3 results:
• Revenues: $12,882M (+51.9%); Immunology: $5,790M (+14.8%); Hematologic Oncology: $1,722M (+16.5%); Neuroscience: $1,249M (>100%); Aesthetics: 967M, Eye Care: $840M.
• Top sellers: Humira: $5,140M (+4.1%); Imbruvica: $1,370M (+9.0%); Skyrizi: $435M (>100%); Venclexta: $352M (+59.0%); Rinvoq: $215M (>100%); Vraylar: $358M; Restasis: $299M; Botox Therapeutic: $523M; Botox Cosmetic: $393M (-43.1%); Mavyret: $414M (-40.6%); Creon: $282M (+5.9%); Linzess/Constella: $248M; Juvederm colletion: $274M.
• Net Income: $2,308M (+22.5%); EPS: $1.29 (+2.4%); non-GAAP Net Income: $5,048M (+45.6%); non-GAAP EPS: $2.83 (+21.5%).
• 2020 guidance (includes Allergan): EPS: $3.89 - 3.91 from $4.12 - 4.22; non-GAAP EPS: $10.47 - 10.49 from $10.35 - 10.45, above consensus of $10.42.
• The Company announces 2021 dividend increase of 10.2%, beginning with dividend payable in February 2021.
• https://seekingalpha.com/news/3629075-abbvie-q3-records-robust-growth-of-100-in-skyrizi-and-rinvoq-sales-non-gaap-eps-guidance